1. Summary Sheet Figures and Maps
Ministry of Health and Public Hygiene, Cote d’Ivoire, Centers for Disease Control and Prevention (CDC), and ICAP at Columbia University. Cote d’Ivoire Population-based HIV Impact Assessment (CIPHIA) : Summary Sheet. Abidjan, Cote d’Ivoire, Atlanta, Georgia and New York, New York, USA: Ministry of Health, CDC and ICAP. July 2018.
The mark “CDC” is owned by the US Dept. of Health and Human Services and is used with permission. Use of this logo is not an endorsement by HHS or CDC of any particular product, service, or enterprise.
This project is supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through CDC under the terms of cooperative agreement #U2GGH The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies
Updated July 2018

2. HIV Prevalence by Age and Sex, CIPHIA 2017-2018
Among adults ages years, HIV prevalence peaks at 8.7% for females ages years and at 5.9% and 6.0% for males ages and years respectively. HIV prevalence is higher among women than men in several age groups, including 20-24, 25-29, 35-39, and years old. This difference is most pronounced among year olds for whom HIV prevalence is approximately sixteen times higher for females (3.2%) than for males (0.2%).
Error bars represent 95% confidence intervals.
HIV prevalence refers to prevalence of HIV-1 and HIV-2

3. HIV Prevalence Among Adults, by Region, CIPHIA 2017-2018
Among adults ages years, prevalence of HIV varies geographically across Côte d’Ivoire, ranging from 1.7 percent in Gôh-Djiboua to 3.4 percent in Abidjan.
HIV prevalence refers to prevalence of HIV-1 and HIV-2

4. Viral Load Suppression Among HIV-Positive People, by Age and Sex, CIPHIA 2017-2018
Prevalence of VLS among people living with HIV in Côte d’Ivoire peaks among older adults at 68.3% among females and 49.3% among males ages years. In contrast, prevalence of VLS is 21.9% among females ages years.
Estimates for males ages and are based on a very small number (less than 25) unweighted cases and have been suppressed. Estimates in parentheses are based on a small number of unweighted cases (25-49) and should be interpreted with caution. Viral load suppression is among only those people living with HIV-1 or HIV-1/2.
Error bars represent 95% confidence intervals.

5. Viral Load Suppression Among HIV-Positive Adults, by Region, CIPHIA 2017-2018
Among HIV-positive adults ages years, prevalence of VLS ranges from 37.3% in Sassandra-Marahoué to 54.6% in Lacs.

6. Achievement of the 90-90-90 Goals Among HIV-Positive Adults, by Sex,
CIPHIA
Error bars represent 95% confidence intervals. Estimates in parentheses are based on a small number of unweighted cases (25-49) and should be interpreted with caution. Inset numbers are conditional proportions. See text above is among only those people living with HIV-1 or HIV-1/2.
90–90–90: An ambitious treatment target to help end the AIDS epidemic By 2020, 90% of all PLHIV will know their HIV status; 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy (ART); and 90% of all people receiving ART will have viral suppression.
Diagnosed In Côte d’Ivoire, 37.2% of PLHIV ages years report knowing their HIV status: 43.2% of HIV-positive females and 24.2% of HIV-positive males know their HIV status.
On Treatment Among PLHIV ages years who know their HIV status, 88.1% self-report current use of ART: 92.6% of HIV-positive females and 70.7% of HIV-positive males who know their HIV status self-report current use of ART.
Virally Suppressed Among PLHIV ages years who self-report current use of ART, 75.9% are virally suppressed: 77.9% of HIV-positive females and 65.2% of HIV-positive males who self-report current use of ART are virally suppressed.
Diagnosed: awareness was defined as self-reporting HIV positive and/ or having a detectable antiretroviral (ARV) in the blood.
On Treatment: being on ART was defined as self-reporting current use of ART and/or having a detectable ARV in the blood.

7. Find the CIPHIA Summary Sheet and additional PHIA Project results at:
phia.icap.columbia.edu
The mark “CDC” is owned by the US Dept. of Health and Human Services and is used with permission. Use of this logo is not an endorsement by HHS or CDC of any particular product, service, or enterprise.
This project is supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through CDC under the terms of cooperative agreement #U2GGH The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies